In recent years, the increasing prevalence of chronic diseases such as cardiovascular disorders and diabetes has led to a surge in the demand for advanced drug delivery systems that enable patients to self-administer their medications.

The human microbiome is characterized by microbial communities that consist of beneficial bacteria, also known as microbiota. The microbiome creates a dynamic ecosystem inside the digestive system, contributing to the overall health of an individual.

Lipid nanoparticles are novel drug delivery systems that enhance treatment outcomes in various ways, including targeting specificity, improving therapeutic efficacy, increasing water solubility, and reducing toxicity.